O'Gorman P - Search Results

1

Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers.

Dunphy K, Dowling P, Bazou D, O'Gorman P. Dunphy K, et al. Cancers (Basel). 2021 Apr 16;13(8):1930. doi: 10.3390/cancers13081930. Cancers (Basel). 2021. PMID: 33923680 Free PMC article. Review.

2

A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.

Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O'Connor R, Kell M, Mitsiades C, Richardson P, Anderson KC, Clynes M, O'Gorman P. Rajpal R, et al. Proteomics. 2011 Apr;11(8):1391-402. doi: 10.1002/pmic.201000471. Epub 2011 Feb 25. Proteomics. 2011. PMID: 21365752

3

Bone disease in multiple myeloma: pathophysiology and management.

Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P. Hameed A, et al. Cancer Growth Metastasis. 2014 Aug 10;7:33-42. doi: 10.4137/CGM.S16817. eCollection 2014. Cancer Growth Metastasis. 2014. PMID: 25187738 Free PMC article. Review.

4

Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.

Dowling P, Hayes C, Ting KR, Hameed A, Meiller J, Mitsiades C, Anderson KC, Clynes M, Clarke C, Richardson P, O'Gorman P. Dowling P, et al. BMC Genomics. 2014 Oct 17;15(1):904. doi: 10.1186/1471-2164-15-904. BMC Genomics. 2014. PMID: 25322877 Free PMC article.

5

Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.

Ting KR, Brady JJ, Hameed A, Le G, Meiller J, Verburgh E, Bayers C, Benjamin D, Anderson KC, Richardson PG, Dowling P, Clynes M, Fitzgibbon MC, O'Gorman P. Ting KR, et al. Br J Haematol. 2016 Apr;173(1):82-8. doi: 10.1111/bjh.13928. Epub 2016 Jan 20. Br J Haematol. 2016. PMID: 26787413 Free article.

6

Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Guang MHZ, McCann A, Bianchi G, Zhang L, Dowling P, Bazou D, O'Gorman P, Anderson KC. Guang MHZ, et al. Leuk Lymphoma. 2018 Mar;59(3):542-561. doi: 10.1080/10428194.2017.1337115. Epub 2017 Jun 13. Leuk Lymphoma. 2018. PMID: 28610537 Free PMC article. Review.

7

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients.

Ting KR, Henry M, Meiller J, Larkin A, Clynes M, Meleady P, Bazou D, Dowling P, O'Gorman P. Ting KR, et al. BBA Clin. 2017 Jun 7;8:28-34. doi: 10.1016/j.bbacli.2017.05.003. eCollection 2017 Dec. BBA Clin. 2017. PMID: 28725572 Free PMC article.

8

Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells.

Kavanagh EL, Lindsay S, Halasz M, Gubbins LC, Weiner-Gorzel K, Guang MHZ, McGoldrick A, Collins E, Henry M, Blanco-Fernández A, O Gorman P, Fitzpatrick P, Higgins MJ, Dowling P, McCann A. Kavanagh EL, et al. Oncogenesis. 2017 Oct 9;6(10):e388. doi: 10.1038/oncsis.2017.82. Oncogenesis. 2017. PMID: 28991260 Free PMC article.

9

Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis.

Guang MHZ, Kavanagh EL, Dunne LP, Dowling P, Zhang L, Lindsay S, Bazou D, Goh CY, Hanley C, Bianchi G, Anderson KC, O'Gorman P, McCann A. Guang MHZ, et al. Cancers (Basel). 2019 Jan 9;11(1):66. doi: 10.3390/cancers11010066. Cancers (Basel). 2019. PMID: 30634515 Free PMC article. Review.

10

Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma.

Lê GN, Bones J, Coyne M, Bazou D, Dowling P, O'Gorman P, Larkin AM. Lê GN, et al. Mol Omics. 2019 Feb 11;15(1):7-20. doi: 10.1039/c8mo00193f. Mol Omics. 2019. PMID: 30652172 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

163 results

Search Page